ARTICLE | Clinical News

Arbutus' ARB-1467 leads to HBsAg responses in Phase IIa for HBV infection

December 1, 2017 9:38 PM UTC

Arbutus Biopharma Corp. (NASDAQ:ABUS) reported data from 11 evaluable hepatitis B e antigen (HBeAg)-negative patients with chronic HBV infection in cohort 4 of the Phase IIa ARB-1467-002 trial showing that 0.4 mg/kg IV ARB-1467 every 2 weeks for 10 weeks led to a response, defined as hepatitis B surface antigen (HBsAg) ≤1000 IU/mL with ≥1 log10 decline, in 7 patients (63%). Five (71%) of the 7 patients who met the responder criteria after 2 doses achieved HBsAG <50 IU/mL. In all 12 patients in cohort 4, the mean reduction in serum HBsAG was 1.4 log10. The candidate was generally well tolerated. The data were presented at the American Association for the Study of Liver Diseases meeting in Washington, D.C.

The single-blind, placebo-controlled, New Zealand and Australian trial enrolled 36 HBeAg-negative or HBeAg-positive, non-cirrhotic patients on stable nucleot(s)ide analog therapy across 4 cohorts. Cohorts 1, 2 and 4 enrolled HBsAg-negative patients to receive 0.2 mg/kg once-monthly ARB-1467, 0.4 mg/kg once-monthly ARB-1467 and 0.4 mg/kg ARB-1467 every other week, respectively. Cohort 3 enrolled HBeAg-positive patients to receive 0.4 mg/kg once-monthly ARB-1467. ...

BCIQ Company Profiles

Arbutus Biopharma Corp.